Summary & Overview
CPT 90651: Nonavalent HPV Vaccine, Intramuscular Administration
CPT code 90651 identifies a nonavalent HPV vaccine administered intramuscularly to protect against nine high-risk and low-risk HPV types. This vaccine is a central preventive tool in reducing HPV-related disease, including cervical and other anogenital cancers and genital warts, and is used in adolescent and young adult immunization programs nationwide. The code covers both two-dose and three-dose schedules, which are applied based on patient age at initiation and clinical guidance.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of clinical context, common service locations, and payer coverage considerations. The publication outlines reimbursement benchmarks, coding nuances specific to vaccine administration, and policy developments that affect access and billing for HPV immunization at a national level.
This summary equips billing professionals, clinic administrators, and health policy stakeholders with essential information on coding 90651, expected sites of service, and the role of the nonavalent HPV vaccine in preventive care. Data not available in the input are noted where applicable in detailed sections.
Billing Code Overview
CPT code 90651 represents a nonavalent human papillomavirus (HPV) vaccine product administered intramuscularly to protect against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). The product can be provided following either a two-dose or three-dose immunization schedule depending on patient age and clinical guidance.
Service Type: Vaccine administration (intramuscular)
Typical Site of Service: Outpatient clinics, primary care offices, pediatric practices, community vaccination clinics, and public health clinics.
Clinical & Coding Specifications
Clinical Context
A 16-year-old adolescent presents to a primary care clinic for routine immunizations. The clinician documents review of immunization history, confirms the patient has not completed the HPV vaccine series, obtains verbal consent, screens for contraindications (severe allergy to a vaccine component, pregnancy), and administers the nonavalent human papillomavirus vaccine intramuscularly in the deltoid. The visit includes vaccine counseling, vaccine administration, and scheduling of the next dose per a two-dose (if initiated before age 15) or three-dose schedule (if initiated at age 15 or older or immunocompromised). Documentation includes vaccine lot number, manufacturer, administration site, route, dose, and informed consent. Billing staff assign CPT code 90651 for the vaccine product and capture any appropriate administration codes and payer-required modifiers. Typical sites of service are outpatient primary care clinics, pediatric offices, school-based health centers, community health clinics, and public health immunization sites.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological amount discarded | When part of the vaccine dose is discarded and payer requires reporting of wasted biologic. |
JZ |